BJMO - volume 12, issue 3, february 2018
E. Seront MD, PhD
Multiple immune checkpoint inhibitors (ICIs) are currently available for the treatment of bladder cancer. The question raised by Dr Seront in his lecture was: “which agent should be used for which patient?”
Read moreBJMO - volume 12, issue 3, february 2018
L. Dirix MD
It has become a yearly tradition during the annual BSMO meeting to have a presentation by Dr Luc Dirix discussing the top stories in oncology over the past year. The 2018 edition was no exception.
Read moreBJMO - volume 11, issue 7, november 2017
P. Specenier MD, PhD
BJMO - volume 11, issue 7, november 2017
L. Triest MD, K. Papadimitriou MD, PhD, M. Rasschaert MD, PhD, J. Van den Brande MD, M. Peeters MD, PhD
ESMO 2017 featured the presentation of several practice changing data in the field of gastrointestinal (GI) cancer. The first part of this report will summarize the key data presented in the field of gastric cancer, gastroesophageal junction (GEJ), biliary, gallbladder, biliary, pancreatic and hepatocellular cancer. In the second part, the focus is turned to colorectal cancer.
(BELG J ONCOL 2017;11(7):340–348)
Read moreBJMO - volume 11, issue 7, november 2017
V. Kruse MD, PhD, L. Brochez MD, PhD, A. Rutten MD
During this year’s ESMO congress a lot of promising new data were presented with regard to melanoma care. We have selected 13 abstracts to discuss here.
(BELG J ONCOL 2017;11(7):334–337)
Read moreBJMO - volume 11, issue 7, november 2017
T. Vermassen PhD, S. Rottey MD, PhD
From the 8th till the 12th of September, Madrid was the host city for the 2017 ESMO Congress. The central theme of the congress was ‘Integrating science into oncology for a better patient outcome’, as it is crucial that researchers and clinicians exchange knowledge in an era of deep understanding of the molecular biology underlying the development of cancer. ESMO 2017 was attended by almost 24,000 registered attendees. This report will highlight eleven key studies concerning genitourinary cancers presented during the meeting.
(BELG J ONCOL 2017;11(7):326–333)
Read moreBJMO - volume 11, issue 7, november 2017
Tom Feys MBA, MSc
ESMO 2017 featured the presentation of several practice changing studies in the field of lung cancer. With respect to immunotherapy, durvalumab showed a benefit for patients with Stage III non-small cell lung cancer (NSCLC) when taken after chemotherapy-radiation. This represents the first major study showing an immunotherapy benefit for patients with lung cancer that is not Stage IV.1 A second key immunotherapy study showed that stage IV NSCLC patients who continued to take nivolumab beyond 1 year had a significantly longer progression-free survival (PFS) than patients who took the drug for 1 year.2
Also in the field of targeted therapy, ESMO 2017 may have induced a paradigm shift. In the phase III FLAURA study, the third-generation EGFR tyrosine kinase inhibitor (TKI) osimertinib, which is already approved for recurrent NSCLC patients harboring an EGFRT790M mutation, was associated with a superior PFS to the current standard of care EGFR-targeted drugs. This was especially the case for patients with brain metastases.3 More positive data in NSCLC patients with brain involvement came from the ALUR trial and from a secondary analysis of the ALEX study, showing that alectinib can significantly decrease central nervous system (CNS) progression of NSCLC, both in the first-line and in the second-line setting.4,5
In addition to this, the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib was shown to be an effective first treatment for BRAFV600E mutated NSCLC.6
A final study worth mentioning in this introduction consists of the IFCT-0302 trial which demonstrated that frequent CT scans after surgery for early-stage lung cancer surgery did not improve survival. This should inform follow-up recommendations and should give patients some peace of mind that they don’t necessarily need CT scans every six months.7
(BELG J ONCOL 2017;11(7):317–325)
Read more
Top
